Therapy of amyotrophic lateral sclerosis remains a challenge

The Lancet Neurology

Volumn 13, Issue 11, 2014, Pages 1062-1063

  van den Berg, Leonard H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CEFTRIAXONE; DEXPRAMIPEXOLE; PLACEBO; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; COGNITION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHENOTYPE; ENVIRONMENTAL FACTOR; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HEREDITY; HUMAN; LIFESTYLE; MOTONEURON; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT RESPONSE; FEMALE; MALE;

AMYOTROPHIC LATERAL SCLEROSIS; CEFTRIAXONE; FEMALE; HUMANS; MALE;

EID: 84907983542     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70179-6     Document Type: Note

References (7)

1. Cudkowicz ME, Titus S, Kearny M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: results of a multi-stage, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 2014, for the Ceftriaxone Study Investigators, published online Oct 6. http://dx.doi.org/10.1016/S1474-4422(14)70222-4.
2. Berry JD, Shefner JM, Conwit R, et al; Northeast ALS Consortium. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 8: e61177.
3. Cudkowicz ME, van den Berg LH, Shefner JM, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol 2013, 12:1059-1067. for the EMPOWER investigators.
4. Bozik ME, Mitsumoto H, Brooks BR, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014, 15:406-413.
5. Van den Berg LH ALS: disease or syndrome?. J Neurol Neurosurg Psych 2011, 82:711.
6. Ravits J, Appel S, Baloh RH, et al. Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 2013, 14(suppl 1):5-18.
7. Chiò A1, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population?. Neurology 2011, 77:1432-1437. PARALS group.